Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Carisma Therapeutics Inc. (SESN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "CARISMA THERAPEUTICS INC. Unaudited Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 76,353 $ 24,194 Marketable securities 40,725 27,802 Prepaid expenses and other assets 5,122 2,596 Total current assets 122,200 54,592 Property and equipment, net 7,590 8,628 Right of use assets – operating leases 3,047 4,822 Restricted cash 30 — Deferred financing costs 146 4,111 Total assets $ 133,013 $ 72,153 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 2,487 $ 1,728 Accrued expenses 9,614 10,361 Deferred revenue 1,416 2,459 Operating lease liabilities 2,486 3,437 Finance lease liabilities 1,215 1,162 Other current liabilities 755 523 Total current liabilities 17,973 19,670 Deferred ..."
05/12/2023 8-K Quarterly results
Docs: "CARISMA THERAPEUTICS INC. Unaudited Consolidated Balance Sheets March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 62,777 $ 24,194 Marketable securities 76,190 27,802 Prepaid expenses and other assets 5,535 2,596 Total current assets 144,502 54,592 Property and equipment, net 8,107 8,628 Right of use assets – operating leases 3,493 4,822 Restricted cash 30 — Deferred financing costs — 4,111 Total assets $ 156,132 $ 72,153 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 4,614 $ 1,728 Accrued expenses 10,187 10,361 Deferred revenue 2,136 2,459 Operating lease liabilities 2,597 3,437 Finance lease liabilities 1,188 1,162 Other current liabilities 755 523 Total current liabilities 21,477 19,670 Deferred ..."
11/07/2022 8-K Quarterly results
Docs: "Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update Sesen Bio"
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update Participated in"
08/09/2021 8-K Quarterly results
Docs: "Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for"
05/10/2021 8-K Quarterly results
Docs: "Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for",
"Sesen Bio, Inc. Corporate Presentation"
11/09/2020 8-K Quarterly results
Docs: "Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in",
"NOVEMBER 2020 BUSINESS UPDATE 1."
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "..1"
05/13/2019 8-K Quarterly results
Docs: "Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer Company Announces Confirmed Meetings with the U.S. Food and Drug Administration in May and June 2019 to Review Registration Strategy for",
"Sesen Bio, Inc. Corporate Presentation"
08/17/2018 8-K Quarterly results
Docs: "Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates FDA Grants Fast Track Designation for Vicinium in NMIBC Company Focused on Defining Registration Pathway for Vicinium and Preparing for BLA Submission in 2019 CAMBRIDGE, Mass., Aug. 14, 2018 – Sesen Bio, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today reported pipeline updates and operating results for the second quarter ended June 30, 2018. “The first half of 2018 was full of successful milestones for Sesen Bio, and I am excited to have joined the company at such an important time in its evolution,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio, who was recently appointed on August 7, 2018. “The thre..."
05/17/2018 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates Company to Host Conference Call in Conjunction with AUA Presentation on May 21, 2018 CAMBRIDGE, Mass., May 15, 2018 - Eleven Biotherapeutics, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today reported pipeline updates and operating results for the quarter ended March 31, 2018. “2018 is set to be a transformational year for the company and, already in the first quarter, we have made important progress in advancing our lead program, Vicinium™ for high-grade non-muscle invasive bladder cancer, or NMIBC,” said Stephen Hurly, president and chief executive officer of Eleven Biotherapeutics. “Our Phase 3 registration trial, th..."
08/14/2017 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results -- Announced Data and Safety Monitoring Board Recommendation to Continue Phase 3 Registration Trial of Vicinium™ as Planned -- -- Entered Collaboration with National Cancer Institute and AstraZeneca to Evaluate Vicinium in Combination with Imfinzi TM in Patients with Non-Muscle Invasive Bladder Cancer -- -- Management to Host Conference Call Today at 8:00 a.m. ET --"
05/04/2017 8-K Form 8-K - Current report
03/24/2017 8-K Form 8-K - Current report
11/14/2016 8-K Form 8-K - Current report
08/12/2016 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update"
05/05/2016 8-K Form 8-K - Current report
03/24/2016 8-K Form 8-K - Current report
11/04/2015 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results Management to host conference call today at 8:30 a.m. ET Cambridge, MA - November 4, 2015 -Eleven Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2015, and recent business highlights. "We made great strides in the advancement of our ophthalmic therapeutics pipeline this quarter. We completed patient enrollment in the first of two planned pivotal Phase 3 clinical trials of isunakinra , for moderate to severe allergic conjunctivitis patients suffering from the late-phase inflammatory response. This Phase 3 study follows completion in 2014 of a Phase 2 clin..."
08/13/2015 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results Management to host conference call today at 8:30 a.m. ET Cambridge, MA, August 13, 2015 - Eleven Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2015, and recent business highlights. "We are continuing to focus on advancing our ocular therapeutics pipeline. We recently initiated a pivotal Phase 3 study of EBI-005 in moderate to severe allergic conjunctivitis patients suffering from the late-phase inflammatory response and are now planning to advance development of EBI-031 for the treatment of diabetic macular edema and uveitis with an IND filing expected in..."
04/30/2015 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports First Quarter 2015 Financial Results"
03/04/2015 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Fourth Quarter and Year-End 2014 Financial Results",
"Eleven Biotherapeutics Reports Fourth Quarter and Year-End 2014 Financial Results"
11/13/2014 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results"
08/13/2014 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results"
05/15/2014 8-K Quarterly results
Docs: "Eleven Biotherapeutics Reports Fiscal First Quarter 2014 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy